The MARGOT/TBCRC052 trial failed to show a significant improvement in pathologic complete response (pCR) rates with margetuximab compared with trastuzumab in patients with early-stage HER2-positive ...

Margetuximab is under clinical development by MacroGenics and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 80% phase transition success ...

Capital structure is the mix of debt and equity that fund a company's operations. A judicious use of debt and equity is a key indicator of a strong balance sheet. A healthy capital structure that ...